Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Clinical trial NCT04919811 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04919811
Sponsor: Nuvation Bio Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer

Start date: 2021-09-01
Primary completion: 2025-06-11
Enrollment: 217

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.